AbCellera Biologics (ABCL)
(Delayed Data from NSDQ)
$2.89 USD
+0.16 (5.86%)
Updated Nov 4, 2024 03:59 PM ET
After-Market: $2.64 -0.25 (-8.65%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.89 USD
+0.16 (5.86%)
Updated Nov 4, 2024 03:59 PM ET
After-Market: $2.64 -0.25 (-8.65%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Wall Street Analysts Believe AbCellera Biologics Inc. (ABCL) Could Rally 138%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for AbCellera Biologics Inc. (ABCL) points to a 137.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Implied Volatility Surging for AbCellera Biologics (ABCL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AbCellera Biologics (ABCL) stock based on the movements in the options market lately.
Implied Volatility Surging for AbCellera (ABCL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -150% and 40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbCellera Biologics Inc. (ABCL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbCellera Biologics Inc. (ABCL) Stock Jumps 9.3%: Will It Continue to Soar?
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -215.66% and 88.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Roblox (RBLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Roblox's (RBLX) first-quarter 2022 performance is expected to have benefited from growth in engagement hours and strength in the user base.
Ring Energy (REI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
A favorable commodity pricing scenario is likely to have aided Ring Energy's (REI) earnings in Q1.
AbCellera Biologics Inc. (ABCL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Much Upside is Left in AbCellera Biologics Inc. (ABCL)? Wall Street Analysts Think 161%
by Zacks Equity Research
The consensus price target hints at a 160.5% upside potential for AbCellera Biologics Inc. (ABCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies
by Zacks Equity Research
AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.
Lilly (LLY) Partners Vir/Glaxo for COVID-19 Combo Regimen
by Zacks Equity Research
Lilly (LLY) collaborates with Vir and Glaxo to develop its COVID-19 therapy, bamlanivimab, in combination with their COVID-19 antibody candidate.